NASDAQ:AZYO Aziyo Biologics - AZYO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aziyo Biologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $4.59 +0.10 (+2.23%) (As of 02/1/2023 12:00 AM ET) Add Compare Share Share Today's Range$4.41▼$4.8250-Day Range$3.48▼$7.4052-Week Range$3.37▼$9.01Volume20,264 shsAverage Volume38,584 shsMarket Capitalization$63.22 millionP/E RatioN/ADividend YieldN/APrice Target$11.17 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Aziyo Biologics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside143.3% Upside$11.17 Price TargetShort InterestHealthy0.11% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.07Based on 4 Articles This WeekInsider TradingAcquiring Shares$3.64 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.60) to ($2.01) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.61 out of 5 starsMedical Sector103rd out of 1,053 stocksBiological Products, Except Diagnostic Industry19th out of 170 stocks 3.5 Analyst's Opinion Consensus RatingAziyo Biologics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.17, Aziyo Biologics has a forecasted upside of 143.3% from its current price of $4.59.Amount of Analyst CoverageAziyo Biologics has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.11% of the float of Aziyo Biologics has been sold short.Short Interest Ratio / Days to CoverAziyo Biologics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aziyo Biologics has recently decreased by 64.09%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAziyo Biologics does not currently pay a dividend.Dividend GrowthAziyo Biologics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AZYO. Previous Next 1.7 News and Social Media Coverage News SentimentAziyo Biologics has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Aziyo Biologics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for AZYO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Aziyo Biologics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aziyo Biologics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $3,637,112.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders39.90% of the stock of Aziyo Biologics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions64.85% of the stock of Aziyo Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aziyo Biologics are expected to grow in the coming year, from ($2.60) to ($2.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aziyo Biologics is -1.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aziyo Biologics is -1.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAziyo Biologics has a P/B Ratio of 4.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Aziyo Biologics (NASDAQ:AZYO) StockAziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device. The company also provides cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons. In addition, it offers Fiber VBM, ViBone, and OsteGro V that are human tissue-derived bone allografts designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues. Further, the company provides contract manufacturing services for various products to corporate customers. It sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. The company was incorporated in 2015 and is headquartered in Silver Spring, Maryland.Read More Receive AZYO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aziyo Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address AZYO Stock News HeadlinesJanuary 26, 2023 | msn.comAziyo Biologics, Inc. (AZYO) Upgraded to Buy: Here's What You Should KnowJanuary 26, 2023 | finance.yahoo.comAre Medical Stocks Lagging Bionano Genomics (BNGO) This Year?February 2, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 21, 2023 | finance.yahoo.comInvestors in Aziyo Biologics (NASDAQ:AZYO) have unfortunately lost 38% over the last yearJanuary 9, 2023 | finance.yahoo.comAziyo Biologics Announces Record Annual Net Sales in Preliminary (Unaudited) Fourth Quarter and Full Year 2022 Topline ResultsJanuary 9, 2023 | nasdaq.comThese 10 Stocks Had The Most Insider Buying Activity During The December QuarterDecember 15, 2022 | finance.yahoo.comAziyo Biologics Announces Funding of Additional $4 Million Term Loan with SWK Holdings CorporationDecember 10, 2022 | finance.yahoo.comChief Financial Officer Matthew Ferguson Just Bought 79% More Shares In Aziyo Biologics, Inc. (NASDAQ:AZYO)February 2, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! December 2, 2022 | msn.comA Look Into Aziyo Biologics' DebtDecember 1, 2022 | msn.comWhat Does Aziyo Biologics' Debt Look Like?December 1, 2022 | msn.comLooking Into Aziyo Biologics's Recent Short InterestDecember 1, 2022 | finance.yahoo.comAziyo Biologics, Inc. Announces Pricing of $11.2 Million Public Offering of Common StockNovember 30, 2022 | finance.yahoo.comAziyo Biologics, Inc. Announces Proposed Public Offering of Common StockNovember 21, 2022 | finance.yahoo.comAziyo Biologics to Participate in Upcoming Investor ConferencesNovember 16, 2022 | finance.yahoo.comAziyo Biologics Third Quarter 2022 Earnings: Misses ExpectationsNovember 15, 2022 | seekingalpha.comAziyo Biologics, Inc. (AZYO) Q3 2022 Earnings Call TranscriptNovember 15, 2022 | finance.yahoo.comAziyo Biologics Reports Strong Third Quarter 2022 RevenueNovember 15, 2022 | finance.yahoo.comAziyo Biologics, Inc. (AZYO) Reports Q3 Loss, Tops Revenue EstimatesNovember 12, 2022 | msn.comPreview: Aziyo Biologics's EarningsNovember 8, 2022 | finance.yahoo.comAziyo Biologics to Report Third Quarter 2022 Financial Results on November 14, 2022November 7, 2022 | finance.yahoo.comWhile individual investors own 33% of Aziyo Biologics, Inc. (NASDAQ:AZYO), private equity firms are its largest shareholders with 36% ownershipOctober 25, 2022 | finance.yahoo.comAziyo Biologics, Inc. (AZYO) Soars 11.7%: Is Further Upside Left in the Stock?October 24, 2022 | finance.yahoo.comAziyo Biologics Appoints Seasoned Healthcare Executive, David Colpman, to Board of DirectorsOctober 11, 2022 | finance.yahoo.comAziyo Biologics Strengthens Leadership Team and Organizes for Growth in Key MarketsOctober 11, 2022 | finance.yahoo.comGreat news for Aziyo Biologics, Inc. (NASDAQ:AZYO): Insiders acquired stock in large numbers last yearAugust 16, 2022 | finance.yahoo.comAziyo’s new CEO wants to build the company into 'an engine.' Here’s his vision.See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AZYO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aziyo Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address AZYO Company Calendar Last Earnings11/14/2022Today2/02/2023Next Earnings (Estimated)3/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AZYO CUSIPN/A CIK1708527 Webwww.aziyobiologics.com Phone240-247-1170Fax510-307-9896Employees176Year FoundedN/APrice Target and Rating Average Stock Price Forecast$11.17 High Stock Price Forecast$13.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+143.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,830,000.00 Net Margins-77.08% Pretax Margin-76.97% Return on Equity-1,819.23% Return on Assets-60.62% Debt Debt-to-Equity RatioN/A Current Ratio1.09 Quick Ratio0.83 Sales & Book Value Annual Sales$47.38 million Price / Sales1.33 Cash FlowN/A Price / Cash FlowN/A Book Value$1.00 per share Price / Book4.59Miscellaneous Outstanding Shares13,774,000Free Float8,278,000Market Cap$63.22 million OptionableNot Optionable Beta-0.19 Key ExecutivesMr. Kevin L. Rakin M.B.A (Age 61)M.S., Exec. Chairman Comp: $77.5kDr. C. Randal Mills Ph.D. (Age 50)Co-Founder, Pres & CEO and Director Comp: $65kMr. Matthew B. Ferguson (Age 54)Chief Financial Officer Comp: $356.64kMr. Thomas Englese (Age 48)Chief Commercial Officer Comp: $396.11kMs. Erica ElchinVP of Global OperationsDr. Michelle LeRoux Williams Ph.D. (Age 47)Chief Scientific Officer Ms. Courtney GuyerVP of MarketingDr. Sonali Fonseca Ph.D.Head of Emerging Bus.esMr. Jeffry D. HametSr. VP of Fin., Treasurer & Sec.More ExecutivesKey CompetitorsSPK AcquisitionNASDAQ:SPKCandel TherapeuticsNASDAQ:CADLAdverum BiotechnologiesNASDAQ:ADVMAptose BiosciencesNASDAQ:APTOJasper TherapeuticsNASDAQ:JSPRView All CompetitorsInsiders & InstitutionsPerkins Capital Management Inc.Bought 40,750 shares on 1/26/2023Ownership: 1.881%David ColpmanBought 3,098 shares on 12/15/2022Total: $12,082.20 ($3.90/share)Brigid MakesBought 2,000 shares on 12/9/2022Total: $7,300.00 ($3.65/share)Highcape Capital, L.P.Bought 735,000 shares on 12/5/2022Total: $3.49 M ($4.75/share)Matthew FergusonBought 22,000 shares on 12/5/2022Total: $102,300.00 ($4.65/share)View All Insider TransactionsView All Institutional Transactions AZYO Stock - Frequently Asked Questions Should I buy or sell Aziyo Biologics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aziyo Biologics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AZYO shares. View AZYO analyst ratings or view top-rated stocks. What is Aziyo Biologics' stock price forecast for 2023? 4 equities research analysts have issued twelve-month target prices for Aziyo Biologics' stock. Their AZYO share price forecasts range from $10.00 to $13.00. On average, they expect the company's stock price to reach $11.17 in the next twelve months. This suggests a possible upside of 143.3% from the stock's current price. View analysts price targets for AZYO or view top-rated stocks among Wall Street analysts. How have AZYO shares performed in 2023? Aziyo Biologics' stock was trading at $4.25 at the beginning of 2023. Since then, AZYO stock has increased by 8.0% and is now trading at $4.59. View the best growth stocks for 2023 here. Are investors shorting Aziyo Biologics? Aziyo Biologics saw a decline in short interest during the month of January. As of January 15th, there was short interest totaling 6,500 shares, a decline of 64.1% from the December 31st total of 18,100 shares. Based on an average daily volume of 32,700 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.1% of the shares of the company are sold short. View Aziyo Biologics' Short Interest. When is Aziyo Biologics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023. View our AZYO earnings forecast. How were Aziyo Biologics' earnings last quarter? Aziyo Biologics, Inc. (NASDAQ:AZYO) issued its quarterly earnings data on Monday, November, 14th. The company reported ($0.73) EPS for the quarter, missing analysts' consensus estimates of ($0.66) by $0.07. The business earned $12.39 million during the quarter, compared to analyst estimates of $12.20 million. Aziyo Biologics had a negative trailing twelve-month return on equity of 1,819.23% and a negative net margin of 77.08%. What guidance has Aziyo Biologics issued on next quarter's earnings? Aziyo Biologics updated its fourth quarter 2022 earnings guidance on Monday, January, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $12.50 million-$12.70 million, compared to the consensus revenue estimate of $12.49 million. When did Aziyo Biologics IPO? (AZYO) raised $49 million in an initial public offering on Thursday, October 8th 2020. The company issued 2,900,000 shares at $16.00-$18.00 per share. Piper Sandler and Cowen acted as the underwriters for the IPO and Cantor and Truist Securities were co-managers. What is Aziyo Biologics' stock symbol? Aziyo Biologics trades on the NASDAQ under the ticker symbol "AZYO." Who are Aziyo Biologics' major shareholders? Aziyo Biologics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Perkins Capital Management Inc. (1.88%). Insiders that own company stock include Brigid Makes, David Colpman, Highcape Capital, LP, Matthew Ferguson, Ronald K Lloyd and Thomas Englese. View institutional ownership trends. How do I buy shares of Aziyo Biologics? Shares of AZYO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Aziyo Biologics' stock price today? One share of AZYO stock can currently be purchased for approximately $4.59. How much money does Aziyo Biologics make? Aziyo Biologics (NASDAQ:AZYO) has a market capitalization of $63.20 million and generates $47.39 million in revenue each year. The company earns $-24,830,000.00 in net income (profit) each year or ($2.84) on an earnings per share basis. How many employees does Aziyo Biologics have? The company employs 176 workers across the globe. How can I contact Aziyo Biologics? The official website for the company is www.aziyobiologics.com. The company can be reached via phone at 240-247-1170, via email at ir@aziyo.com, or via fax at 510-307-9896. This page (NASDAQ:AZYO) was last updated on 2/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.